ProShares Big Data Refiners ETF (ARCA: DAT)

Últimas noticias sobre ProShares Big Data Refiners ETF (ARCA:DAT)

Technology

Communication Services

Other

The Fund invests in financial instruments that ProShare Advisors believes, in combination, should track the performance of the Index. The Index is designed to measure the performance of companies that provide services related to analytics, software, hardware, and computing infrastructure for managing and extracting information from large structured and unstructured data sets. The Index includes companies in at least one of nine FactSet Revere Business Industry Classification System Sub-Industries (RBICS Sub-Industries) that the index provider has identified as big data related. The nine eligible RBICS Sub-Industries are (1) Business Intelligence Software, (2) Business Intelligence/Data Warehousing Consulting, (3) Customer Service Software, (4) Data Storage Infrastructure Software, (5) Enterprise Middleware Software, (6) Government and Public Service Industry Software, (7) Information Storage Systems, (8) Network Administration Software, and (9) Peripheral and Other Commerce Equipment Makers. Companies in these sub-industries are selected if they receive 75 percent or more of their revenue from one or more of those sub-industries. Selected companies are then weighted based on their market capitalization, subject to a 4.5 percent limit.

Microstrategy Inc

Commvault Systems Inc

Zebra Technologies Corp

Nutanix Inc A

Tyler Technologies Inc

Confluent Inc-Class A

Informatica Llc

Palantir Technologies Inc.

Nice Ltd

Elastic Nv

Rubrik Inc-A

Dynatrace Inc

Snowflake, Inc., Class A

Interdigital Inc

Proshares Big Data Refiners ETF

ProShares Big Data Refiners ETF

Streamr

DIGITAL ASST MONTARY NTWK by Digital Asset Monetary Network, Inc.

Digital Asset Monetary Network Inc

DatChat Inc

DATWYLER HOLDING AG by Datwyler Holding AG

Daetwyler Holding AG

Trading Ideas

LXEH

Lixiang Education Holding Shares Halted On Circuit Breaker To The Downside, Stock Now Down -23.7%

UBS analyst Peter Grom maintains YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) with a Neutral and lowers the price target from $43 to $31.

News

Price Target

Analyst Ratings

YETI

UBS Maintains Neutral on YETI Holdings, Lowers Price Target to $31

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $629.44, with a high estimate of $715.00 and a low estimate of $475.00. Experiencing a 2.53% decline, the current average is now lower than the previous average price target of $645.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1744916464_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Thermo Fisher Scientific by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $580.00&#x7C;$680.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $475.00&#x7C;$620.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $570.00&#x7C;$650.00 &#x7C; 
&#x7C;Sung Ji Nam &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $650.00&#x7C;$605.00 &#x7C; 
&#x7C;Andrew Cooper &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $667.00&#x7C;$650.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $650.00&#x7C;$600.00 &#x7C; 
&#x7C;Dan Leonard &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $715.00&#x7C;$700.00 &#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $680.00&#x7C;$660.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $678.00&#x7C;$647.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Thermo Fisher Scientific. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Thermo Fisher Scientific compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Thermo Fisher Scientific's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Thermo Fisher Scientific's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TMO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Thermo Fisher Scientific analyst ratings.</a>
<h2>All You Need to Know About Thermo Fisher Scientific</h2>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
<h3>Understanding the Numbers: Thermo Fisher Scientific's Finances</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3M period, Thermo Fisher Scientific showcased positive performance, achieving a revenue growth rate of 4.68% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Thermo Fisher Scientific's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.06% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.71%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Thermo Fisher Scientific's ROA stands out, surpassing industry averages. With an impressive ROA of 1.85%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Thermo Fisher Scientific's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.63.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Thermo Fisher Scientific: Insights From 9 Financial Analysts

Financial giants have made a conspicuous bullish move on JD.com. Our analysis of options history for JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) revealed 33 unusual trades.
Delving into the details, we found 60% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 17 were puts, with a value of $1,703,637, and 16 were calls, valued at $1,066,568.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $40.0 for JD.com during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for JD.com's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of JD.com's whale trades within a strike price range from $30.0 to $40.0 in the last 30 days. 
<h3>JD.com Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744916463_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.4</td>
<td>$4.3</td>
<td>$4.37</td>
<td>$37.50</td>
<td>$681.7K</td>
<td>16.6K</td>
<td>2.0K</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.39</td>
<td>$1.35</td>
<td>$1.38</td>
<td>$31.00</td>
<td>$344.9K</td>
<td>1.4K</td>
<td>2.5K</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$8.85</td>
<td>$8.55</td>
<td>$8.82</td>
<td>$35.00</td>
<td>$131.9K</td>
<td>580</td>
<td>205</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.5</td>
<td>$6.45</td>
<td>$6.49</td>
<td>$30.00</td>
<td>$129.7K</td>
<td>3.3K</td>
<td>518</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.5</td>
<td>$6.45</td>
<td>$6.48</td>
<td>$30.00</td>
<td>$116.6K</td>
<td>3.3K</td>
<td>180</td>
</tr>
</tbody>
</table>

<h3>About JD.com</h3>
JD.com is the third-largest Chinese e-commerce platform by GMV in 2024. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
In light of the recent options history for JD.com, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of JD.com</h3>
<ul>
<li>Currently trading with a volume of 9,543,647, the JD's price is down by -0.76%, now at $35.06. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 28 days.</li>
</ul>
<h3>Expert Opinions on JD.com</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $48.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on JD.com with a target price of $48. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest JD.com options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

This Is What Whales Are Betting On JD.com

Deep-pocketed investors have adopted a bullish approach towards Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 73 extraordinary options activities for Advanced Micro Devices. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 57% leaning bullish and 30% bearish. Among these notable options, 45 are puts, totaling $3,121,011, and 28 are calls, amounting to $1,915,075.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $60.0 to $260.0 for Advanced Micro Devices during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Advanced Micro Devices's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Advanced Micro Devices's whale activity within a strike price range from $60.0 to $260.0 in the last 30 days. 
<h3>Advanced Micro Devices Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744916458_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/25/25</td>
<td>$2.46</td>
<td>$2.43</td>
<td>$2.45</td>
<td>$87.00</td>
<td>$502.2K</td>
<td>1.1K</td>
<td>4.0K</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/17/27</td>
<td>$29.6</td>
<td>$29.25</td>
<td>$29.4</td>
<td>$100.00</td>
<td>$441.0K</td>
<td>824</td>
<td>167</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$10.5</td>
<td>$10.4</td>
<td>$10.45</td>
<td>$85.00</td>
<td>$209.0K</td>
<td>11.1K</td>
<td>955</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$3.85</td>
<td>$3.75</td>
<td>$3.8</td>
<td>$110.00</td>
<td>$155.4K</td>
<td>2.6K</td>
<td>1.2K</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$4.85</td>
<td>$4.85</td>
<td>$4.85</td>
<td>$70.00</td>
<td>$130.4K</td>
<td>5.8K</td>
<td>413</td>
</tr>
</tbody>
</table>

<h3>About Advanced Micro Devices</h3>
Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.
After a thorough review of the options trading surrounding Advanced Micro Devices, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Advanced Micro Devices Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 25,325,341, with AMD's price down by -0.68%, positioned at $87.69.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 19 days.</li>
</ul>
<h3>What The Experts Say On Advanced Micro Devices</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $124.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on Advanced Micro Devices, which currently sits at a price target of $100. 
&#x2A; An analyst from Jefferies has revised its rating downward to Hold, adjusting the price target to $120. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Advanced Micro Devices with a target price of $120. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Advanced Micro Devices with a target price of $126. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Advanced Micro Devices, targeting a price of $155. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Advanced Micro Devices options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Advanced Micro Devices's Options Frenzy: What You Need to Know

Across the recent three months, 5 analysts have shared their insights on Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $130.6, a high estimate of $133.00, and a low estimate of $124.00. This current average has increased by 1.87% from the previous average price target of $128.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1744916456_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Itron is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $133.00&#x7C;$133.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $133.00&#x7C;$135.00 &#x7C; 
&#x7C;Kashy Harrison &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $124.00&#x7C;$119.00 &#x7C; 
&#x7C;Austin Moeller &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $132.00&#x7C;$130.00 &#x7C; 
&#x7C;Noah Kaye &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $131.00&#x7C;$124.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Itron. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Itron compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Itron's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Itron's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITRI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Itron analyst ratings.</a>
<h2>Discovering Itron: A Closer Look</h2>
Itron Inc provides solutions that measure, manage, and analyze energy and water use. It operates under the Itron brand and manages and reports under three operating segments: Device Solutions, Networked Solutions, and Outcomes. The Device Solutions segment includes hardware products used for measurement, control, or sense that do not have communications capability embedded for use with broader Itron systems. The Networked Solutions segment includes a combination of communicating devices, network infrastructure, and associated application software designed and sold as a complete solution. The Outcome segment includes their value-added, enhanced software and services which manage, organize, analyze, and interpret data to improve decision-making and maximize operational profitability.
<h3>Unraveling the Financial Story of Itron</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, Itron showcased positive performance, achieving a revenue growth rate of 6.18% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Itron's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.48%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Itron's ROE excels beyond industry benchmarks, reaching 4.24%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.72%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 0.91, Itron faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ITRI

Beyond The Numbers: 5 Analysts Discuss Itron Stock

Investors with a lot of money to spend have taken a bearish stance on Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with FICO, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Fair Isaac.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 60%, bearish.
Out of all of the options we uncovered, 9 are puts, for a total amount of $479,660, and there was 1 call, for a total amount of $29,189.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $1760.0 and $2550.0 for Fair Isaac, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Fair Isaac's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Fair Isaac's significant trades, within a strike price range of $1760.0 to $2550.0, over the past month.
<h3>Fair Isaac 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744916453_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FICO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$154.1</td>
<td>$150.0</td>
<td>$154.05</td>
<td>$1920.00</td>
<td>$77.0K</td>
<td align="right">65</td>
<td align="right">25</td>
</tr>
<tr>
<td>FICO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$153.0</td>
<td>$150.0</td>
<td>$153.0</td>
<td>$1920.00</td>
<td>$76.5K</td>
<td align="right">65</td>
<td align="right">10</td>
</tr>
<tr>
<td>FICO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$147.6</td>
<td>$141.0</td>
<td>$144.75</td>
<td>$1900.00</td>
<td>$72.3K</td>
<td align="right">14</td>
<td align="right">0</td>
</tr>
<tr>
<td>FICO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$644.0</td>
<td>$635.0</td>
<td>$635.0</td>
<td>$2550.00</td>
<td>$63.5K</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>FICO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$158.0</td>
<td>$154.0</td>
<td>$158.0</td>
<td>$1920.00</td>
<td>$47.4K</td>
<td align="right">65</td>
<td align="right">4</td>
</tr>
</tbody>
</table>

<h3>About Fair Isaac</h3>
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
In light of the recent options history for Fair Isaac, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Fair Isaac's Current Market Status</h3>
<ul>
<li>With a trading volume of 64,822, the price of FICO is up by 1.13%, reaching $1921.17.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 12 days from now.</li>
</ul>
<h3>What The Experts Say On Fair Isaac</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $2375.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $2500. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Fair Isaac, targeting a price of $2250. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Fair Isaac, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

FICO

This Is What Whales Are Betting On Fair Isaac

Throughout the last three months, 4 analysts have evaluated F N B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.25, a high estimate of $20.00, and a low estimate of $16.00. Highlighting a 2.67% decrease, the current average has fallen from the previous average price target of $18.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1744916444_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of F N B among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Manuel Navas &#x7C;DA Davidson &#x7C;Maintains &#x7C;Buy &#x7C; $19.00&#x7C;$19.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $16.00&#x7C;$18.00 &#x7C; 
&#x7C;Frank Schiraldi &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $18.00&#x7C;$19.00 &#x7C; 
&#x7C;Russell Gunther &#x7C;DA Davidson &#x7C;Raises &#x7C;Buy &#x7C; $20.00&#x7C;$19.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to F N B. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of F N B compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for F N B's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of F N B's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FNB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on F N B analyst ratings.</a>
<h2>Delving into F N B's Background</h2>
F N B Corp provides a full range of financial services, principally to consumers, corporations, governments and small- to medium-sized businesses. It has three reportable business segments: Community Banking, Wealth Management and Insurance. The majority of revenue is from the Community banking segment. It offers commercial &amp; consumer banking services. Commercial banking solutions include corporate banking, small business banking, investment real estate financing, business credit, capital markets &amp; lease financing. Consumer banking products &amp; services include deposit products, mortgage lending, &amp; consumer lending &amp; a complete suite of mobile &amp; online banking services.
<h3>Unraveling the Financial Story of F N B</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining F N B's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.36% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: F N B's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 29.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): F N B's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.75%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): F N B's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.23%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: F N B's debt-to-equity ratio stands notably higher than the industry average, reaching 0.59. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

F N B Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">9</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $147.19, a high estimate of $250.00, and a low estimate of $100.00. This current average represents a 11.86% decrease from the previous average price target of $167.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744916435_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Advanced Micro Devices among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Timothy Arcuri &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $155.00&#x7C;$175.00 &#x7C; 
&#x7C;Aaron Rakers &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $120.00&#x7C;$140.00 &#x7C; 
&#x7C;Mark Lipacis &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;Outperform &#x7C; $126.00&#x7C;$147.00 &#x7C; 
&#x7C;Christopher Danely &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $100.00&#x7C;$110.00 &#x7C; 
&#x7C;Blayne Curtis &#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $120.00&#x7C;$135.00 &#x7C; 
&#x7C;Vijay Rakesh &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $120.00&#x7C;$140.00 &#x7C; 
&#x7C;Cody Acree &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $170.00&#x7C;$170.00 &#x7C; 
&#x7C;Vijay Rakesh &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $140.00&#x7C;$160.00 &#x7C; 
&#x7C;Ruben Roy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $162.00&#x7C;$200.00 &#x7C; 
&#x7C;Christopher Rolland &#x7C;Susquehanna &#x7C;Lowers &#x7C;Positive &#x7C; $150.00&#x7C;$165.00 &#x7C; 
&#x7C;Harsh Kumar &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $140.00&#x7C;$180.00 &#x7C; 
&#x7C;Joseph Moore &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $137.00&#x7C;$147.00 &#x7C; 
&#x7C;Aaron Rakers &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $140.00&#x7C;$165.00 &#x7C; 
&#x7C;Cody Acree &#x7C;Benchmark &#x7C;Lowers &#x7C;Buy &#x7C; $170.00&#x7C;$200.00 &#x7C; 
&#x7C;Vivek Arya &#x7C;B of A Securities &#x7C;Lowers &#x7C;Neutral &#x7C; $135.00&#x7C;$155.00 &#x7C; 
&#x7C;John Vinh &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $140.00&#x7C;$150.00 &#x7C; 
&#x7C;Joseph Moore &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $147.00&#x7C;$158.00 &#x7C; 
&#x7C;Hans Mosesmann &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $250.00&#x7C;$250.00 &#x7C; 
&#x7C;Christopher Rolland &#x7C;Susquehanna &#x7C;Lowers &#x7C;Positive &#x7C; $165.00&#x7C;$200.00 &#x7C; 
&#x7C;Ben Reitzes &#x7C;Melius Research &#x7C;Lowers &#x7C;Hold &#x7C; $129.00&#x7C;$160.00 &#x7C; 
&#x7C;Christopher Danely &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $175.00&#x7C;$200.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Advanced Micro Devices. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Advanced Micro Devices compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Advanced Micro Devices's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AMD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Advanced Micro Devices analyst ratings.</a>
<h2>Delving into Advanced Micro Devices's Background</h2>
Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.
<h3>Advanced Micro Devices: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Advanced Micro Devices's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 24.16%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Advanced Micro Devices's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 6.29%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Advanced Micro Devices's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.84%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Advanced Micro Devices's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.69%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.04.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

21 Analysts Have This To Say About Advanced Micro Devices

Motorola Solutions's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) short percent of float has risen 13.33% since its last report. The company recently reported that it has 2.23 million shares sold short, which is 1.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Motorola Solutions Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744916431_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Motorola Solutions has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Motorola Solutions's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Motorola Solutions's peer group average for short interest as a percentage of float is 6.80%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About Motorola Solutions?

UBS analyst Josh Silverstein maintains Tourmaline Oil (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TOU#TSX">TOU</a>) with a Neutral and lowers the price target from C$74 to C$71.

TSX:TOU

UBS Maintains Neutral on Tourmaline Oil, Lowers Price Target to C$71

Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $89.8, a high estimate of $110.00, and a low estimate of $70.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.1%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744916426_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Lumentum Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-------------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Samik Chatterjee &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $73.00&#x7C;$105.00 &#x7C; 
&#x7C;Simon Leopold &#x7C;Raymond James &#x7C;Lowers &#x7C;Strong Buy &#x7C; $82.00&#x7C;$96.00 &#x7C; 
&#x7C;Dave Kang &#x7C;B. Riley Securities &#x7C;Raises &#x7C;Neutral &#x7C; $75.00&#x7C;$62.00 &#x7C; 
&#x7C;Simon Leopold &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $96.00&#x7C;$94.00 &#x7C; 
&#x7C;Ruben Roy &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $105.00&#x7C;$95.00 &#x7C; 
&#x7C;David Vogt &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $96.00&#x7C;$93.00 &#x7C; 
&#x7C;Mike Genovese &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $110.00&#x7C;$110.00 &#x7C; 
&#x7C;Tim Savageaux &#x7C;Northland Capital Markets&#x7C;Raises &#x7C;Market Perform &#x7C; $70.00&#x7C;$60.00 &#x7C; 
&#x7C;Ryan Koontz &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $110.00&#x7C;$110.00 &#x7C; 
&#x7C;Meta Marshall &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $81.00&#x7C;$83.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lumentum Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Lumentum Holdings compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Lumentum Holdings's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Lumentum Holdings's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LITE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Lumentum Holdings analyst ratings.</a>
<h2>About Lumentum Holdings</h2>
Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.
<h3>Lumentum Holdings: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Lumentum Holdings's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 9.65%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Lumentum Holdings's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -15.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -6.89%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Lumentum Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.53%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.99, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LITE

Deep Dive Into Lumentum Holdings Stock: Analyst Perspectives (10 Ratings)

AES's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) short percent of float has fallen 7.71% since its last report. The company recently reported that it has 28.15 million shares sold short, which is 4.55% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.26 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>AES Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744916425_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AES has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AES's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AES's peer group average for short interest as a percentage of float is 6.25%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into AES's Recent Short Interest

In the current market session, Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) price is at $283.64, after a 1.10% increase. However, over the past month, the stock decreased by 12.83%, and in the past year, by 1.36%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744916420_0.png" alt="Past Year Chart" />

<h3>Comparing Cummins P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 24.3 in the Machinery industry, Cummins Inc. has a lower P/E ratio of 9.89. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744916420_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

A Look Into Cummins Inc's Price Over Earnings

Progressive's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) short percent of float has fallen 12.93% since its last report. The company recently reported that it has 5.89 million shares sold short, which is 1.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Progressive Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744916420_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Progressive has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Progressive's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Progressive's peer group average for short interest as a percentage of float is 2.41%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Progressive?

Analysts' ratings for Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $111.33, a high estimate of $125.00, and a low estimate of $96.00. Experiencing a 7.14% decline, the current average is now lower than the previous average price target of $119.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1744916419_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Merck &amp; Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Vamil Divan &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $115.00&#x7C;$115.00 &#x7C; 
&#x7C;James Shin &#x7C;Deutsche Bank &#x7C;Lowers &#x7C;Hold &#x7C; $105.00&#x7C;$128.00 &#x7C; 
&#x7C;Vamil Divan &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $115.00&#x7C;$122.00 &#x7C; 
&#x7C;Tim Anderson &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $112.00&#x7C;$118.00 &#x7C; 
&#x7C;Evan David Seigerman&#x7C;BMO Capital &#x7C;Lowers &#x7C;Market Perform &#x7C; $96.00&#x7C;$105.00 &#x7C; 
&#x7C;Andrew Baum &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $115.00&#x7C;$125.00 &#x7C; 
&#x7C;Terence Flynn &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $106.00&#x7C;$113.00 &#x7C; 
&#x7C;Andrew Baum &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $125.00&#x7C;$130.00 &#x7C; 
&#x7C;Terence Flynn &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $113.00&#x7C;$123.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Merck &amp; Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merck &amp; Co compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Merck &amp; Co's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MRK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merck &amp; Co analyst ratings.</a>
<h2>Unveiling the Story Behind Merck &amp; Co</h2>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
<h3>Merck &amp; Co's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining Merck &amp; Co's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.79% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Merck &amp; Co's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 23.96%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Merck &amp; Co's ROE stands out, surpassing industry averages. With an impressive ROE of 8.24%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.19%, the company showcases effective utilization of assets.
Debt Management: Merck &amp; Co's debt-to-equity ratio is below the industry average. With a ratio of 0.8, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Merck & Co: Insights From 9 Financial Analysts

J.B. Hunt Transport Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) trades higher Thursday. This comes after a <a href="https://www.benzinga.com/news/guidance/25/04/44827812/jb-hunt-q1-earnings-revenue-beat-eps-miss-shares-skid">lackluster earnings report.</a> First quarter earnings per share came in at $1.17, while analysts were looking for $1.19.
Traders are watching how the stock reacts around the important $128.00 level.&nbsp; Two weeks ago it was support. Now it is resistance. This is why it is our Stock of the Day.
Most volume for a stock typically trades at the opening and closing prices. This is why short-term traders need to know where these levels have recently been in their stocks. Because a lot of volume trades at these prices, they can become support and resistance levels.
Previous highs and lows on a day can be important as well. This isn't because heavy volume typically trades at them. It's more due to investor and trader psychology.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/04/44868280/us-listed-chinese-stocks-face-250-billion-forced-selling-risk-as-delisting-fears-emerge-what-investors-need-to-know">US-Listed Chinese Stocks Face $250 Billion Forced Selling Risk As Delisting Fears Emerge: What Investors Need To Know</a>
As you can see on the chart below, the low trades on Friday, April 4, Monday, April 7, Tuesday, April 8, and Friday, April 11 were close to $128. The opening price on Wednesday, April 9 was $128.22.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="549" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17145349/one7-1024x549.png" alt="" class="wp-image-877463" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17145349/one7-1024x549.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17145349/one7-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17145349/one7-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17145349/one7-1536x824.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17145349/one7.png 1557w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Now that the stock has dropped below $128, many traders and investors who bought it around this price regret doing so. Some decide to sell if they can get out at breakeven.
They placed sell orders at or around $128. This is why there was resistance there yesterday. It was the opening price, and then the shares sold off over the course of the day and closed almost four points lower. And as for now, they seem to have found resistance there again in Thursday's trading.
If this resistance breaks, meaning JBHT trades and holds above it, it will illustrate an important dynamic. It will mean that the sellers have either finished or canceled their orders. This could set the stage for a move higher because buyers will have to outbid each other to draw sellers into the market.
Savvy traders understand the importance of knowing where the recent opens, closes, highs, and lows have been. This allows them to profit.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;</a></li>
</ul>
Image: Shutterstock

Technicals

JBHT

Stock Of The Day: Is J.B. Hunt Heading Higher?

FuboTV Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) has <a href="https://www.benzinga.com/pressreleases/25/04/b44862704/fubo-retains-exclusive-rights-to-premier-league-in-canada-with-multi-year-agreement-beginning-with">secured a multi-year deal </a>to maintain its exclusive streaming rights for the English Premier League in Canada. 
The sports-focused live television platform confirmed it will continue to stream every Premier League match, starting with the 2025/2026 season, under the renewed agreement.
Fubo initially acquired the exclusive Canadian rights to the Premier League in 2022. The renewal strengthens the streamer's foothold in the soccer content space, where it already carries multiple high-profile leagues and tournaments across Europe and the Americas.
&#8220;The Premier League is considered the most prestigious soccer league globally and we are proud to remain the exclusive home of this elite competition in Canada,&#8221; said Ben Grad, senior VP of strategic partnerships and operations.
&#8220;Fubo was founded with the mission to stream premium soccer and a range of sports for consumers, and we&#8217;ve built a strong audience by carrying leagues that Canadians are passionate about.&#8221;
Also Read: <a href="https://www.benzinga.com/trading-ideas/dividends/25/04/44863342/retail-giant-costco-raises-dividend-by-12">Retail Giant Costco Raises Dividend By 12%</a>
The platform offers a wide array of soccer programming in Canada, including exclusive rights to Serie A, Coppa Italia, and the Supercoppa Italiana. 
Additionally, matches from Ligue 1, the Canadian national teams, and Copa Libertadores are part of its soccer lineup. Fubo will stream all 380 Premier League games per season.
&#8220;The Premier League has many passionate fans in Canada, and Fubo does an excellent job making the competition available to them. We look forward to working together over the coming seasons as we continue to showcase the excitement of the league to both new and existing fans,&#8221; said Paul Molnar, chief media officer at the Premier League.
Fubo also offers coverage of a wide range of sports. In Canada, its programming slate also includes action from the NBA, MLB, NHL, and IPL cricket league.
Subscribers gain access to over 100 live channels spanning sports, news, and entertainment.
Fubo's service is optimized for accessibility, allowing users to stream content through web browsers or a variety of devices including Amazon Fire TV, Android, Apple TV, Chromecast, Roku, LG TV, Samsung, Xbox One, and more. 
Price Action: FUBO was trading 1.57% higher at $2.91 per share at last check on Thursday.
Read Next: <a href="https://www.benzinga.com/25/04/44825498/bofa-downgrades-pepsico-as-analyst-sees-limited-potential-until-2026">PepsiCo Still A Buy? Not Anymore As Analysts &#8216;Run Out Of Answers&#8217;</a>
Photo: Shutterstock

Sports

Media

General

FUBO

Fubo Extends Soccer Reign In Canada With Premier League Renewal

WIIM

MUFG

SMFG

Shares of US-listed Japanese banking companies are trading higher amid US-Japan trade negotiations. Japan's adjusted trade balance data may indicate strength in the Yen, which may support BOJ policymaker desires.

<ul>
<li>The agreement would facilitate providing Tevogen Bio with in-house cell therapy production capabilities</li>
<li>Formalized agreement aligns with previously announced topline forecasts</li>
</ul>
WARREN, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ChauyjKAkjVQc82z3r0-HRiCdl_h57jCJfQO7_H90fvBO4Qc7TOYUc07tsnddJm85Vb-6HNe-IecYXiwfhMnsA==">Tevogen Bio</a> ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>), today announced it has entered into an agreement with CD 8 Technology Services LLC ("CD8") for the development and/or acquisition of a turn-key facility that is intended to support both in-house pre-clinical research and GMP cell therapy production capabilities.
Tevogen Bio will provide the primary staff and operations for the facility, which is a key component of the company's long-term strategy to accelerate development timelines, maintain operational agility, and control cost. Tevogen Bio believes that this agreement should allow the Company to overcome significant capital barriers of entry that are typically faced in building GMP capabilities at scale. The agreement has an initial term of 12 months and will automatically renew and aligns with the previously announced topline forecasts.

Comments

ProShares Big Data Refiners ETF

Noticias

Últimas noticias sobre ProShares Big Data Refiners ETF (ARCA:DAT)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL